Prelude Therapeutics Inc (PRLD) Earnings Report, Financial Results, Financial analysis

Prelude Therapeutics Inc narrowed first quarter of 2023 net loss per share of $-0.58 compare to net loss per share of $-2.43 recorded in the same quarter a year ago a decrease compare to $0.00 realized in previous quarter.

*first quarter of 2023*
Earnings Per Share	Revenues
$ -0.58	$ 0 Mill
$+1.85	Unch.

Prelude Therapeutics Inc's Revenue fell by 0 % in first quarter of 2023 (Mar 31 2023) year on year, to $0 million and declined by sequentially.

Prelude Therapeutics Inc is Expected to report next financial results on August 08, 2023.

More on PRLD's Income Statement

PRLD's NET INCOME

Prelude Therapeutics Inc's in thefirst quarter of 2023 recorded net loss of $-27.718 million, an improvement compare to net loss of $-111.694 million in 2021 a year ago.

Sequentially company realized a net loss, compared to net income of $111.694 million in the previous quarter.

More on PRLD's Growth

Prelude Therapeutics Inc Inventories
In Mar 31 2023 company's net cash and cash equivalents decreased by $-12 million, capital expenditures grew by -65.13%, to $-1 millions compare to same quarter a year ago and fell by 16.38% from IV. Quarter (Dec 31 2022).

More on PRLD's Cash flow Statement

Earnings quality

Prelude Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Prelude Therapeutics Inc payed $ -0.64 cash per share, on a free-cash flow basis .

Book value fell by -11.11 % sequentially to $3.67 per share, -15.19% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.67 per share from $ 4.13.

Company issued 0.43 million shares or 0.90 % in Mar 31 2023.

• More on PRLD's Dividends

Market Capitalization (Millions)	259
Shares Outstanding (Millions)	48
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	-
Net Income (TTM) (Millions $)	-31
Cash Flow (TTM) (Millions $)	169
Capital Exp. (TTM) (Millions $)	-2
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	11

Earnings quality

Prelude Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Prelude Therapeutics Inc had negative $ -0.64 cash flow per share, on a free-cash flow basis .

Book value fell by -11.11 % sequentially to $3.67 per share, -15.19% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.67 per share from $ 4.13.

Company issued 0.43 million shares or 0.90 % in Mar 31 2023.

• More on PRLD's Balance Sheets

Market Capitalization (Millions)	259
Shares Outstanding (Millions)	48
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	-
Net Income (TTM) (Millions $)	-31
Cash Flow (TTM) (Millions $)	169
Capital Exp. (TTM) (Millions $)	-2
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	11

Prelude Therapeutics Inc

PRLD's Financial Statements and Analysis